Last update 30 Nov 2025

Beijing Suncadia Pharmaceuticals Co., Ltd

Subsidiary Company|2019|Beijing Shi, China

Overview

Basic Info

Introduction
Founded in 2019 in the Yizhuang district, Beijing Suncadia Pharmaceuticals Co., Ltd is an affiliate of the Jiangsu Hengrui Medicine Co., Ltd. The parent company, which was established in 1970, specializes in the innovation, development, production, and marketing of high-quality pharmaceutical products. It made its debut on the Shanghai Stock Exchange in the year 2000.

Tags

Cardiovascular Diseases
Nervous System Diseases
Endocrinology and Metabolic Disease
Monoclonal antibody
Biological products
Chemical drugs

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases4
Endocrinology and Metabolic Disease3
Neoplasms1
Top 5 Drug TypeCount
Biological products3
Small molecule drug2
Chemical drugs2
Monoclonal antibody2
Top 5 TargetCount
FXIa(Factor XIa)1
ANGPTL3(Angiopoietin like 3)1
Lp(a)(lipoprotein(a))1
SUR1(Sulfonylurea receptor 1)1

Related

9
Drugs associated with Beijing Suncadia Pharmaceuticals Co., Ltd
SHR-1918
Target
ANGPTL3
Mechanism
ANGPTL3 inhibitors
Active Org.
Beijing Suncadia Pharmaceuticals Co., Ltd [+1]
Originator Org.
Beijing Suncadia Pharmaceuticals Co., Ltd
Active Indication
Hyperlipidemia, Familial Combined [+1]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
SHR-2004
Target
FXIa
Mechanism
factor XIa inhibitors
Active Org.
Beijing Suncadia Pharmaceuticals Co., Ltd [+1]
Originator Org.
Beijing Suncadia Pharmaceuticals Co., Ltd
Active Indication
Arterial thrombosis [+6]
Inactive Indication-
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
HRS-8179
Target
SUR1
Mechanism
SUR1 inhibitors
Active Org.
Beijing Suncadia Pharmaceuticals Co., Ltd
Originator Org.
Beijing Suncadia Pharmaceuticals Co., Ltd
Active Indication
Brain Edema
Inactive Indication
Stroke
Drug Highest PhasePhase 2/3
First Approval Ctry. / Loc.-
First Approval Date-
22
Clinical Trials associated with Beijing Suncadia Pharmaceuticals Co., Ltd
NCT07230145
/ Not yet recruitingPhase 1
A Double-Blind, Randomized, Dose-Escalating Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Dose SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure
NCT07230730
/ Not yet recruitingPhase 3
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia
NCT07133815
/ Not yet recruitingPhase 2
A Multicenter, Single Arm, Open Label Phase II Clinical Study Evaluating the Long-term Efficacy and Safety of SHR-1918 in Homozygous Familial Hypercholesterolemia Patients
100 Clinical Results associated with Beijing Suncadia Pharmaceuticals Co., Ltd
Login to view more data
0 Patents (Medical) associated with Beijing Suncadia Pharmaceuticals Co., Ltd
Login to view more data
100 Deals associated with Beijing Suncadia Pharmaceuticals Co., Ltd
Login to view more data
100 Translational Medicine associated with Beijing Suncadia Pharmaceuticals Co., Ltd
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 Dec 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Application
1
4
Phase 1
Phase 2
1
3
Phase 3
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
SHR-2004
 ( FXIa )		Arterial thrombosis
More
Phase 3
SHR-1918
 ( ANGPTL3 )		Homozygous familial hypercholesterolemia
More
Phase 3
HRS-8179
 ( SUR1 )		Brain Edema
More
Phase 2/3
HRS-5346
 ( Lp(a) )		lipoprotein Disorder
More
Phase 2
HRS-4029
Acute Ischemic Stroke
More
Phase 1
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free